Disclosures: Wen Zhang: Nothing to Disclose, Wenyue Wu: Nothing to Disclose, Ning Zhang: Nothing to Disclose, Hong Li: Nothing to Disclose, Yameng Sun: Nothing to Disclose, Xiaodong Ge: Nothing to Disclose, Hui Han: Nothing to Disclose, Shuyan Chen: Nothing to Disclose, Anjian Xu: Nothing to Disclose, Sai Santosh Babu Komakula: Nothing to Disclose, Chao Wang: Nothing to Disclose, Nithyananthan Subramaniyam: Nothing to Disclose, Qi Han: Nothing to Disclose, Xuzhen Yan: Nothing to Disclose, Aiting Yang: Nothing to Disclose, Natalia Nieto: Nothing to Disclose, Hong You: Nothing to Disclose, Wei Chen: Nothing to Disclose 2043 NOVEL BLOOD-BASED BIOMARKER MODEL FOR DIAGNOSIS OF HEPATIC FIBROSIS IN MASLD Eveline Gart Lars Verschuren 1 Anne Mak 2 Andre Boonstra 3 Joanne Verheij 4 Lise Lotte Gluud 5 Adriaan Holleboom 2 Maarten Tushuizen 6 , 1 TNO, 2 Amsterdam UMC, 3 Erasmus University Medical Center, 4 Academic Medical Center, 5 Copenhagen University - Hvidovre Hospital, 6 LUMC Background: Considering the escalating prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) and related fibrosis, accurate non-invasive biomarkers for diagnosis and staging of fibrosis are urgently needed
Wen et al., 2025), cardiomyopathies, pulmonary hypertension (Mocumbi et al., 2024), ischemia reperfusion injury (Sharp et al., 2014) and metabolic syndromes (obesity, hyperglycemia, and a range of liver problems) (Muraresku et al., 2018
It's great at making the body release more growth hormone
Heald Aged Nez Perce Recalls the 1877 Tragedy by Rowena L
BPC 157 medication fully counteracts these disturbances ( p 0.05, at least, vs
